Zenas BioPharma (ZBIO)

Executive Summary

Zenas BioPharma is a clinical-stage biopharmaceutical company focused on developing innovative antibody and biologic therapies for autoimmune diseases. The company employs an asset-centric strategy, advancing late-stage programs with validated mechanisms of action to address high unmet medical needs. Zenas’ lead product, obexelimab, is a CD19 x FcγRIIB bispecific antibody being evaluated in multiple indications, including a Phase 3 trial in warm autoimmune hemolytic anemia (wAIHA) and Phase 2 trials in systemic lupus erythematosus (SLE) and multiple sclerosis (MS). Additionally, the company is developing orelabrutinib, a Bruton’s tyrosine kinase inhibitor, in Phase 3 for primary and secondary progressive MS. Zenas went public in 2024 and has a market valuation of approximately $1.2 billion. The company’s pipeline is supported by a strong scientific foundation and a clear regulatory pathway, positioning it for potential value inflection points in the near term. With key data readouts expected in the second half of 2026, Zenas is approaching a critical period. The Phase 3 wAIHA trial of obexelimab is scheduled to complete in August 2026, with topline data anticipated shortly thereafter. Positive results could support a Biologics License Application filing and address a significant unmet need in a rare autoimmune hemolytic disorder. Additionally, Phase 2 data in SLE and MS are expected in late 2026. The SLE program targets a large market with limited effective therapies, while the MS program addresses progressive forms of the disease with high morbidity. Successful outcomes could substantially de-risk the pipeline and drive significant shareholder value.

Upcoming Catalysts (preview)

• Q3 2026Obexelimab Phase 3 wAIHA topline data60% success
• Q4 2026Obexelimab Phase 2 SLE topline data55% success
• Q3 2026Obexelimab Phase 2 relapsing MS data50% success